Qiagen NV
QIA
Company Profile
Business description
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Contact
Hulsterweg 82
VenloLI5912 PL
NLDT: +31 773556600
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
5,800
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
Current operating conditions are challenging but over the long-term prospects are better.
stocks
Why Guzman and Reece's share reversals have a lot in common
Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,477.30 | 20.70 | -0.24% |
| CAC 40 | 8,126.26 | 75.19 | 0.93% |
| DAX 40 | 22,701.96 | 291.69 | 1.30% |
| Dow JONES (US) | 43,621.16 | 159.95 | 0.37% |
| FTSE 100 | 8,708.74 | 40.07 | 0.46% |
| HKSE | 23,787.93 | 753.91 | 3.27% |
| NASDAQ | 19,026.39 | 260.54 | -1.35% |
| Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
| NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
| S&P 500 | 5,955.25 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
| SSE Composite Index | 3,380.21 | 34.17 | 1.02% |